- Quizartinib (AC220)
- Cabozantinib (XL184, BMS-907351)
- TG101209
- Amuvatinib (MP-470, HPK 56)
- G-749
| AST 487RET kinase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Related Biological Data
| Description | AST487 is an inhibitor of RET kinase with IC50 value of 0.88 μM. | |||||
| Targets | RET kinase | |||||
| IC50 | 0.88 μM | |||||
| Cell experiment [1]: | |
Cell lines | Baf3 cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reaction Conditions | 10 min; IC50=34±4 nmol/L |
Applications | Data derived from a panel of Baf3 murine pro–B cell lymphoma lines rendered growth factor–independent by transduction with various activated tyrosine kinases, suggested cellular specificity for RET-driven proliferation (IC50 for PTC3-RET–driven Baf3 cells, 34±4 nmol/L), with activity against FLT3 as well, and to a lesser extent,Bcr-ABL–dependent proliferation |
| Animal experiment [1]: | |
Animal models | Female athymic nude mice |
Dosage form | 50 mg/kg; oral taken |
Applications | NVP-AST487 given p.o. evoked a dose-dependent inhibition of growth of NIH3T3-RETC634W xenografts, with doses >30 mg/kg/d causing significant reductions in tumor size. The effects of the compound on RET expression and phosphorylation in tumor extracts was analyzed 6 h following the final treatment. Reductions in tumor RET phosphorylation in NVP-AST487–treated animals were clearly seen, particularly at doses ≥30 mg/kg. Interestingly, there was also a dose-dependent decrease of RET expression, with one of three tumors analyzed in the 30 mg/kg group and three of three tumors in the 50 mg/kg group showing a dramatic reduction in RET protein levels. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin[J]. Cancer research, 2009, 69(15): 6232-6240. | |
AST 487 Dilution Calculator
calculate
AST 487 Molarity Calculator
calculate
| Cas No. | 630124-46-8 | SDF | Download SDF |
| Synonyms | NVP-AST 487 | ||
| Chemical Name | 1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea | ||
| Canonical SMILES | CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)NC3=CC=C(C=C3)OC4=NC=NC(=C4)NC)C(F)(F)F | ||
| Formula | C26H30F3N7O2 | M.Wt | 529.56 |
| Solubility | ≥26.5 mg/mL in DMSO, ≥51.2 mg/mL in EtOH, <2.54 mg/ml="" in="" h2o=""> | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
AST487 is an inhibitor of RET kinase with IC50 value of 0.88μM [1].
AST487 belongs to the N,N’-diphenyl urea class. It inhibit the activity of RET kinase as well as many other kinases( such as KDR, Flt-3 and c-Kit) in vitro. In the cell assay, the inhibition effect of AST487 is displayed both in PC-RET/PTC3 cells and TT cells, which harbor an endogenous activating point mutation of RET (RETC634W). AST487 decreases RET autophosphorylation and activation of PLCγ and ERK with a dose-dependent manner. Additionally, AST487 is also found to inhibit the growth of human thyroid cancer cell lines with RET, but not BRAF mutations. It supports the selectivity of AST487 for RET. In vivo assay shows that AST487 causes significant reductions in the size of NIH3T3-RETC634W xenografts with doses >30 mg/kg/d and oral administration of AST487 at 50 or 30 mg/kg/d decreases mean tumor volume in mice [1].
References:[1] Nagako Akeno-Stuart, Michelle Croyle, Jeffrey A. Knauf, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007, 67:6956-6964.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
近期，上海公卫临床研究中心的一位研究生应用两种转染试剂Turbofecttransfectionreagent（Thermo）和EntransterTM-R4000（Engreen）进行了一次RNA转染比较。比较情况如下：
实验方法
转染试剂：Turbofecttransfectionreagent（Thermo）和EntransterTM-R4000（EngreenBiosystemCo,Ltd）
待处理细胞：humanCD8+T细胞
1.针对Turbofect转染的方法
每孔培养体积均为100μL，细胞数目在105左右。
取0.5μLagomir，加入9.5μL无血清RPMI1640，充分混匀；
取0.2μLTurbofecttransfectionreagent和agomir稀释液充分混合。
转染复合物制备完成；混匀后室温下孵育15-20分钟，直接取10μL加入已铺好细胞的孔中，继续培养24h收取细胞，用PBS洗涤3次以上，以备RNA抽提。
转染Mix的配制：100nMago/N.C.：（0.5μLagomir+0.2μLTurbofect+9.3μL无血清的RPMI1640）×2.5=1.25+0.5+23.25
2.EntransterTM-R4000转染
每孔培养体积均为100μL，细胞数目在105左右。
取0.5μLagomir，加入9.5μL无血清RPMI1640，充分混匀，制成10μLagomir稀释液；
取0.25μLEntransterTM-R4000，然后加入9.75μL无血清稀释液体，充分混匀，制成10μLEntransterTM-R4000稀释液；
将EntransterTM-R4000稀释液和agomir稀释液充分混合（可用振荡器或加样器吹吸10次以上），室温静置15分钟。
转染复合物制备完成；
将20μL转染复合物加入孔中的细胞悬液中，前后移动培养皿，混合均匀；
转染后6h观察细胞状态，并更换培养基，继续培养24h后收取细胞，用PBS洗涤3次以上，以备RNA抽提。
转染Mix的配制：100nMago/N.C.：（0.5μLagomir+9.5μL无血清的RPMI1640）×2.5=1.25+23.75；Etranster稀释液：（0.25μLEtranster+9.75μL无血清的RPMI1640）×5=1.25+48.75（室温静置5分钟），取20μL至ago和N.C.管中，室温静置15分钟。
实验结果
结论：从目的miRNA表达水平的检测结果来看，转染24h后，英格恩生物公司（EngreenBiosystem）的EntransterTM-R4000(ago/NC:422912倍)转染试剂的效果优于Turbofect转染试剂(ago/NC:285870倍)。
讨论：从实验结果来看，英格恩生物公司（EngreenBiosystem）的EntranstenTM-R4000(ago/NC:422912倍)转染试剂的效果优于Turbofect转染试剂(ago/NC:285870倍)。EntransterTM-R4000是英格恩生物（EngreenBiosystem）最新研发合成的针对siRNA、microRNA、mimic、inhibitor、mRNA和shRNA等RNA的转染试剂。EntransterTM-R4000不仅可以转染小RNA，而且针对mRNA等长链RNA优化。该试剂可将RNA导入多种细胞系，包括原代细胞和悬浮细胞。无论有无血清、抗生素存在均可获得很高的转染效率。
但是在选择的时候，也需要注意其他的一些问题。
1、采用何种原料和抗体，是否高效、灵敏、特异
2、规范包被操作，吸附是否均匀
3、重复性、可靠性
6、是否提供技术服务
7、适用于血浆、血清、组织匀浆液、细胞培养上清液、尿液等多种类型的样本
8、可检测动物类型是否丰富
9、可检测指标是否齐全
elisa试剂盒就查下博欧特生物
使用方法：
1、 血清：操作过程中避免任何细胞刺激。使用不含热原和内毒素的试管。收集血液后，1000×g离心10分钟将血红细胞迅速小心地分离。
2、 血浆：EDTA、柠檬酸盐、肝素血浆可用于检测。1000×g离心30分钟去除颗粒。
3、 细胞上清液：1000×g离心10分钟去除颗粒和聚合物。
4、 组织匀浆：将组织加入适量生理盐水捣碎。1000×g离心10分钟，取上清液。
5、 保存：如果样品不立即使用，应将其分成小部分-70℃保存，避免反复冷冻。尽可能的不要使用溶血或高血脂血。如果血清中大量颗粒，检测前先离心或过滤。不要在37℃或更高的温度加热解冻。应在室温下解冻并确保样品均匀地充分解冻。
—DNA转染试剂Polyjet-适用于普遍的哺乳动物细胞
LipoD293-适用于悬浮细胞的转染（包括昆虫细胞SF9）-对于普遍的哺乳动物细胞具有更优异的转染效率
—DNAandsiRNA转染试剂
Lipojet-适用于大多数哺乳动物细胞的转染-低毒性（无需换液）-用量少-DNA/RNA共转染（co-transfection）-效果优于Lipofectamine2000
—siRNA转染试剂
GenMute-适用于大多数哺乳动物细胞转染-低毒性（无需换液）-用量少-DNA/siRNA共转染（co-transfection）PepMute-适用于普遍的哺乳动物细胞的转染
如题，PolyplusTransfection转染试剂在中国区的代理商有哪些？求推荐1-2个靠谱的，谢谢！
想用RNAiMAX或者lipo2000转染siRNA，但是看了下转染试剂的说明书和锐博的siRNA说明书，觉得分别对siRNA的用量描述差别挺大的呀，不知道到底该参考哪个呢。
以24孔板为例在siRNA说明书中写到，siRNA终浓度是50nM的话，加入浓度为20μM的siRNA1.25ul，每孔体积是500ul，那这样的话，每孔最终siRNA的量是25pmol。
但是在RNAiMAX或者是lipo2000说明书中，一个写的每孔siRNA用量是5pmol，一个是500ng，这与siRNA厂家所提供的量相差也太多了吧。
到底该看哪一个呢。
ps.一旦siRNA的量和体积确定下来之后，转染试剂的量和siRNA1:1的加就可以了吗？
请各位大神解答。
1.siRNA说明书中的用量，红线圈出
2.RNAIMAX说明书中siRNA的用量。
3.lipo2000说明书中siRNA用量
